z-logo
open-access-imgOpen Access
Recurrent DNA copy number alterations in intestinal-type sinonasal adenocarcinoma
Author(s) -
J. Perez-Escuredo,
A. Lopez-Hernandez,
María Costales,
F. Lopez,
S.P. Ares,
Blanca Vivanco,
José Luís Llorente,
Mario Hermsen
Publication year - 2016
Publication title -
rhinology (amsterdam. online)/rhinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.275
H-Index - 57
eISSN - 1996-8604
pISSN - 0300-0729
DOI - 10.4193/rhino15.382
Subject(s) - multiplex ligation dependent probe amplification , adenocarcinoma , medicine , microarray , pathological , copy number variation , pathology , gene , genetics , cancer research , biology , genome , cancer , exon , gene expression
Background: Intestinal-type sinonasal adenocarcinoma (ITAC) is a rare tumour related to occupational wood dust exposure. Few studies have described recurrent genetic changes on a genome-wide scale. The aim of this study was to obtain a high resolution map of recurrent genetic alterations in ITAC. Material and methods: Copy number alterations were evaluated by microarray CGH and MLPA in 37 primary tumours. The results were correlated with pathological characteristics and clinical outcome. Results: Microarray CGH identified the following recurrent aberrations, in descending order: gains at 5p15 (22 cases, 60%), 8q24 (21 cases, 57%), 20q13 (20 cases, 54%), 20q11, and 8q21 (19 cases, 51%), 20p13, and 7p11 (16 cases, 43%), and losses at 5q11-qter, 8p12-pter, and 18q12-23 (15 cases, 40%), and 17p13, and 19p13 (13 cases, 35%). MLPA analysis confirmed this global pattern of gains and losses. Chromosomal loss at 4q32-ter and gains at 1q22, 6p22 and 3q29, as well as deletion of TIMP2 and CRK correlated with unfavourable clinical outcome. Conclusion: ITACs have a unique pattern of chromosomal abnormalities. The four different histological subtypes of ITAC appeared genetically similar. Four chromosomal gains and losses and two specific genes showed prognostic value and may be involved in tumour progression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here